Subcutaneous Amivantimab: Overcoming Treatment Barriers and Shaping Advanced NSCLC Strategies

August 23, 2024

By Martin Dietrich, MD, PhD
Wade Iams, MD

Opinion

Video

Focusing on treatment practices for patients with advanced EGFR-mutant NSCLC, Martin Dietrich, MD, PhD, discusses how the availability of subcutaneous amivantamab can potentially address current treatment barriers.

EP: 1.Assessing FLAURA2's Influence: How Has It Shaped Your First-Line Treatment Strategy?

EP: 2.Evaluating MARIPOSA’s Secondary Analysis in High-Risk Advanced EGFR-Mutant NSCLC: Practical Implications

EP: 3.Expert Insights from PALOMA-3: Highlights from ASCO 2024

Now Viewing

EP: 4.Subcutaneous Amivantimab: Overcoming Treatment Barriers and Shaping Advanced NSCLC Strategies

EP: 5.Implementing Proactive Management Strategies with Amivantamab in Clinical Practice: Expert Insights

EP: 6.Insights from TROPION-Lung05 and HERTHENA-Lung01: Perspectives on the Future Role of ADCs in Advanced EGFR-Mutant NSCLC

EP: 7.Other Trials and Emerging Data in EGFR-Mutant NSCLC Treatment: Anticipating the Future Treatment Landscape

Video content above is prompted by the following:

How may the availability of subcutaneous amivantamab:
- Address current treatment barriers/challenges and expand treatment options for patients with advanced NSCLC?
- Impact 1L and 2L treatment strategies and the future role of amivantamab?

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!